nodes	percent_of_prediction	percent_of_DWPC	metapath
Trimetrexate—Phosphatase alkaline increased—Vismodegib—skin cancer	0.0569	0.0569	CcSEcCtD
Trimetrexate—Blood alkaline phosphatase increased—Vismodegib—skin cancer	0.0474	0.0474	CcSEcCtD
Trimetrexate—Hepatotoxicity—Vemurafenib—skin cancer	0.0455	0.0455	CcSEcCtD
Trimetrexate—Hyponatraemia—Vismodegib—skin cancer	0.0414	0.0414	CcSEcCtD
Trimetrexate—Aspartate aminotransferase increased—Vismodegib—skin cancer	0.0372	0.0372	CcSEcCtD
Trimetrexate—Hepatotoxicity—Dactinomycin—skin cancer	0.0257	0.0257	CcSEcCtD
Trimetrexate—Hepatotoxicity—Temozolomide—skin cancer	0.0232	0.0232	CcSEcCtD
Trimetrexate—Hypocalcaemia—Dactinomycin—skin cancer	0.0217	0.0217	CcSEcCtD
Trimetrexate—Phosphatase alkaline increased—Temozolomide—skin cancer	0.018	0.018	CcSEcCtD
Trimetrexate—Fatigue—Vismodegib—skin cancer	0.0175	0.0175	CcSEcCtD
Trimetrexate—Hepatotoxicity—Docetaxel—skin cancer	0.0155	0.0155	CcSEcCtD
Trimetrexate—Blood alkaline phosphatase increased—Temozolomide—skin cancer	0.015	0.015	CcSEcCtD
Trimetrexate—Asthenia—Vismodegib—skin cancer	0.0146	0.0146	CcSEcCtD
Trimetrexate—Pruritus—Vismodegib—skin cancer	0.0144	0.0144	CcSEcCtD
Trimetrexate—Aspartate aminotransferase increased—Dactinomycin—skin cancer	0.013	0.013	CcSEcCtD
Trimetrexate—Vomiting—Vismodegib—skin cancer	0.0129	0.0129	CcSEcCtD
Trimetrexate—Rash—Vismodegib—skin cancer	0.0128	0.0128	CcSEcCtD
Trimetrexate—Dermatitis—Vismodegib—skin cancer	0.0128	0.0128	CcSEcCtD
Trimetrexate—Blood bilirubin increased—Docetaxel—skin cancer	0.0126	0.0126	CcSEcCtD
Trimetrexate—Nausea—Vismodegib—skin cancer	0.012	0.012	CcSEcCtD
Trimetrexate—Phosphatase alkaline increased—Docetaxel—skin cancer	0.0119	0.0119	CcSEcCtD
Trimetrexate—Aspartate aminotransferase increased—Temozolomide—skin cancer	0.0117	0.0117	CcSEcCtD
Trimetrexate—Neutropenia—Dactinomycin—skin cancer	0.0116	0.0116	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Temozolomide—skin cancer	0.0115	0.0115	CcSEcCtD
Trimetrexate—Convulsion—Imiquimod—skin cancer	0.0113	0.0113	CcSEcCtD
Trimetrexate—Fatigue—Vemurafenib—skin cancer	0.0108	0.0108	CcSEcCtD
Trimetrexate—Neutropenia—Temozolomide—skin cancer	0.0105	0.0105	CcSEcCtD
Trimetrexate—Blood alkaline phosphatase increased—Docetaxel—skin cancer	0.00996	0.00996	CcSEcCtD
Trimetrexate—Body temperature increased—Vemurafenib—skin cancer	0.00991	0.00991	CcSEcCtD
Trimetrexate—Fatigue—Imiquimod—skin cancer	0.00921	0.00921	CcSEcCtD
Trimetrexate—Asthenia—Vemurafenib—skin cancer	0.00899	0.00899	CcSEcCtD
Trimetrexate—Pruritus—Vemurafenib—skin cancer	0.00887	0.00887	CcSEcCtD
Trimetrexate—Feeling abnormal—Imiquimod—skin cancer	0.00881	0.00881	CcSEcCtD
Trimetrexate—Hyponatraemia—Docetaxel—skin cancer	0.0087	0.0087	CcSEcCtD
Trimetrexate—Anaemia—Bleomycin—skin cancer	0.0086	0.0086	CcSEcCtD
Trimetrexate—Body temperature increased—Imiquimod—skin cancer	0.00845	0.00845	CcSEcCtD
Trimetrexate—Anaemia—Dactinomycin—skin cancer	0.00802	0.00802	CcSEcCtD
Trimetrexate—Vomiting—Vemurafenib—skin cancer	0.00797	0.00797	CcSEcCtD
Trimetrexate—Rash—Vemurafenib—skin cancer	0.0079	0.0079	CcSEcCtD
Trimetrexate—Dermatitis—Vemurafenib—skin cancer	0.00789	0.00789	CcSEcCtD
Trimetrexate—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.0078	0.0078	CcSEcCtD
Trimetrexate—Asthenia—Imiquimod—skin cancer	0.00767	0.00767	CcSEcCtD
Trimetrexate—Confusional state—Bleomycin—skin cancer	0.00766	0.00766	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Docetaxel—skin cancer	0.00764	0.00764	CcSEcCtD
Trimetrexate—Pruritus—Imiquimod—skin cancer	0.00756	0.00756	CcSEcCtD
Trimetrexate—Nausea—Vemurafenib—skin cancer	0.00744	0.00744	CcSEcCtD
Trimetrexate—Thrombocytopenia—Bleomycin—skin cancer	0.00743	0.00743	CcSEcCtD
Trimetrexate—Anaemia—Temozolomide—skin cancer	0.00725	0.00725	CcSEcCtD
Trimetrexate—Neutropenia—Docetaxel—skin cancer	0.007	0.007	CcSEcCtD
Trimetrexate—Thrombocytopenia—Dactinomycin—skin cancer	0.00693	0.00693	CcSEcCtD
Trimetrexate—Convulsion—Temozolomide—skin cancer	0.0068	0.0068	CcSEcCtD
Trimetrexate—Vomiting—Imiquimod—skin cancer	0.00679	0.00679	CcSEcCtD
Trimetrexate—Rash—Imiquimod—skin cancer	0.00674	0.00674	CcSEcCtD
Trimetrexate—Dermatitis—Imiquimod—skin cancer	0.00673	0.00673	CcSEcCtD
Trimetrexate—Anaemia—Fluorouracil—skin cancer	0.00668	0.00668	CcSEcCtD
Trimetrexate—Confusional state—Temozolomide—skin cancer	0.00646	0.00646	CcSEcCtD
Trimetrexate—Nausea—Imiquimod—skin cancer	0.00635	0.00635	CcSEcCtD
Trimetrexate—Thrombocytopenia—Temozolomide—skin cancer	0.00627	0.00627	CcSEcCtD
Trimetrexate—Convulsion—Fluorouracil—skin cancer	0.00626	0.00626	CcSEcCtD
Trimetrexate—Feeling abnormal—Bleomycin—skin cancer	0.00626	0.00626	CcSEcCtD
Trimetrexate—Fatigue—Dactinomycin—skin cancer	0.0061	0.0061	CcSEcCtD
Trimetrexate—Body temperature increased—Bleomycin—skin cancer	0.006	0.006	CcSEcCtD
Trimetrexate—Confusional state—Fluorouracil—skin cancer	0.00595	0.00595	CcSEcCtD
Trimetrexate—Feeling abnormal—Dactinomycin—skin cancer	0.00583	0.00583	CcSEcCtD
Trimetrexate—Thrombocytopenia—Fluorouracil—skin cancer	0.00578	0.00578	CcSEcCtD
Trimetrexate—Body temperature increased—Dactinomycin—skin cancer	0.0056	0.0056	CcSEcCtD
Trimetrexate—Fatigue—Temozolomide—skin cancer	0.00552	0.00552	CcSEcCtD
Trimetrexate—Asthenia—Bleomycin—skin cancer	0.00545	0.00545	CcSEcCtD
Trimetrexate—Pruritus—Bleomycin—skin cancer	0.00537	0.00537	CcSEcCtD
Trimetrexate—Feeling abnormal—Temozolomide—skin cancer	0.00528	0.00528	CcSEcCtD
Trimetrexate—Asthenia—Dactinomycin—skin cancer	0.00508	0.00508	CcSEcCtD
Trimetrexate—Body temperature increased—Temozolomide—skin cancer	0.00506	0.00506	CcSEcCtD
Trimetrexate—Feeling abnormal—Fluorouracil—skin cancer	0.00486	0.00486	CcSEcCtD
Trimetrexate—Vomiting—Bleomycin—skin cancer	0.00483	0.00483	CcSEcCtD
Trimetrexate—Anaemia—Docetaxel—skin cancer	0.00482	0.00482	CcSEcCtD
Trimetrexate—Rash—Bleomycin—skin cancer	0.00479	0.00479	CcSEcCtD
Trimetrexate—Dermatitis—Bleomycin—skin cancer	0.00478	0.00478	CcSEcCtD
Trimetrexate—Body temperature increased—Fluorouracil—skin cancer	0.00466	0.00466	CcSEcCtD
Trimetrexate—Asthenia—Temozolomide—skin cancer	0.00459	0.00459	CcSEcCtD
Trimetrexate—Pruritus—Temozolomide—skin cancer	0.00453	0.00453	CcSEcCtD
Trimetrexate—Convulsion—Docetaxel—skin cancer	0.00452	0.00452	CcSEcCtD
Trimetrexate—Nausea—Bleomycin—skin cancer	0.00451	0.00451	CcSEcCtD
Trimetrexate—Vomiting—Dactinomycin—skin cancer	0.0045	0.0045	CcSEcCtD
Trimetrexate—Rash—Dactinomycin—skin cancer	0.00446	0.00446	CcSEcCtD
Trimetrexate—Confusional state—Docetaxel—skin cancer	0.00429	0.00429	CcSEcCtD
Trimetrexate—Nausea—Dactinomycin—skin cancer	0.00421	0.00421	CcSEcCtD
Trimetrexate—Pruritus—Fluorouracil—skin cancer	0.00417	0.00417	CcSEcCtD
Trimetrexate—Thrombocytopenia—Docetaxel—skin cancer	0.00417	0.00417	CcSEcCtD
Trimetrexate—Vomiting—Temozolomide—skin cancer	0.00407	0.00407	CcSEcCtD
Trimetrexate—Rash—Temozolomide—skin cancer	0.00404	0.00404	CcSEcCtD
Trimetrexate—Dermatitis—Temozolomide—skin cancer	0.00403	0.00403	CcSEcCtD
Trimetrexate—Nausea—Temozolomide—skin cancer	0.0038	0.0038	CcSEcCtD
Trimetrexate—Vomiting—Fluorouracil—skin cancer	0.00375	0.00375	CcSEcCtD
Trimetrexate—Rash—Fluorouracil—skin cancer	0.00372	0.00372	CcSEcCtD
Trimetrexate—Dermatitis—Fluorouracil—skin cancer	0.00372	0.00372	CcSEcCtD
Trimetrexate—Fatigue—Docetaxel—skin cancer	0.00367	0.00367	CcSEcCtD
Trimetrexate—Feeling abnormal—Docetaxel—skin cancer	0.00351	0.00351	CcSEcCtD
Trimetrexate—Nausea—Fluorouracil—skin cancer	0.0035	0.0035	CcSEcCtD
Trimetrexate—Body temperature increased—Docetaxel—skin cancer	0.00337	0.00337	CcSEcCtD
Trimetrexate—Asthenia—Docetaxel—skin cancer	0.00306	0.00306	CcSEcCtD
Trimetrexate—Pruritus—Docetaxel—skin cancer	0.00301	0.00301	CcSEcCtD
Trimetrexate—Vomiting—Docetaxel—skin cancer	0.00271	0.00271	CcSEcCtD
Trimetrexate—Rash—Docetaxel—skin cancer	0.00269	0.00269	CcSEcCtD
Trimetrexate—Dermatitis—Docetaxel—skin cancer	0.00268	0.00268	CcSEcCtD
Trimetrexate—Nausea—Docetaxel—skin cancer	0.00253	0.00253	CcSEcCtD
